0001209191-23-005596.txt : 20230130
0001209191-23-005596.hdr.sgml : 20230130
20230130200846
ACCESSION NUMBER: 0001209191-23-005596
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230126
FILED AS OF DATE: 20230130
DATE AS OF CHANGE: 20230130
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: de Garidel Marc
CENTRAL INDEX KEY: 0001901033
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41201
FILM NUMBER: 23569804
MAIL ADDRESS:
STREET 1: C/O CINCOR PHARMA, INC.
STREET 2: 200 CLARENDON STREET, 6TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CinCor Pharma, Inc.
CENTRAL INDEX KEY: 0001868734
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 230 THIRD AVE., 6TH FLOOR
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 8445311834
MAIL ADDRESS:
STREET 1: 230 THIRD AVE., 6TH FLOOR
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-26
0
0001868734
CinCor Pharma, Inc.
CINC
0001901033
de Garidel Marc
C/O CINCOR PHARMA, INC
230 THIRD AVENUE, 6TH FLOOR
WALTHAM
MA
02451
1
1
0
0
Chief Executive Officer
Common Stock
2023-01-26
4
A
0
200000
A
212500
D
Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-fourth (1/4) of the RSUs shall vest on January 26, 2024 and the remaining RSUs shall vest in three (3) equal annual installments thereafter, subject to the Reporting Person's continuous service through each such vesting date; provided that, in the event the previously announced pending acquisition of the Issuer by AstraZeneca PLC occurs, 50% of the RSUs shall vest immediately prior to the closing of such transaction, subject to the Reporting Person's continuous service through such date, and the remaining 50% of the RSUs shall be cancelled as of such date.
/s/ Cathy Rude, Attorney-in-Fact
2023-01-30